Complete response after sorafenib therapy for hepatocellular carcinoma in an HIV-HBV co infected patient: Possible synergy with HAART ? A case report.
A significant proportion of HIV patients, ranging between 5-67%, are co-infected with hepatitis B virus (HBV). Several studies suggest an increasing incidence of hepatocellular carcinoma (HCC) in HIV infected individuals. We report the case of a 69 years old male co infected with HBV and HIV who developed HCC. The patient was unfit for curative approach and he underwent three sessions of transcatheter arterial chemoembolisation (TACE). After the last session the disease assessment showed progression and sorafenib therapy was initiated. Highly active antiretroviral therapy (HAART) was continued during sorafenib treatment. The patient achieved a radiological complete response (CR) after 6 months of therapy and remained with no sign of HCC progression at subsequent assessment. Meanwhile, patient's HIV and HBV infections remained stable. Regarding toxicity the patient developed grade 3 hand foot skin reaction (HFSR) that required 50% dose reduction of sorafenib, grade 3 hypertension and grade 2 diarrhea. In conclusion this is the first case of successful treatment of HCC in a HIV-HBV co-infected patient and only the second report of the co administration of sorafenib with HAART.
Chelis
Leonidas
L
Department of Medical Oncology, Democritus University of Thrace, 68100 Thrace, Alexandroupolis, Dragana, Greece. chelisleonidas@yahoo.gr
Ntinos
Napoleon
N
Souftas
Vasilios
V
Deftereos
Savas
S
Xenidis
Nikolaos
N
Chamalidou
Elen
E
Maltezos
Eustratios
E
Kakolyris
Stylianos
S
D000368:Aged; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods; D001557:Benzenesulfonates / Q000008:administration & dosage*; D006528:Carcinoma, Hepatocellular / Q000150:complications / Q000188:drug therapy* / Q000821:virology; D060085:Coinfection / Q000188:drug therapy / Q000821:virology; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy*; D006509:Hepatitis B / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D008113:Liver Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000821:virology; D008297:Male; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines / Q000008:administration & dosage*; D000077157:Sorafenib; D016896:Treatment Outcome
D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib
N Engl J Med. 2008 Jul 24;359(4):378-90
18650514
Lancet Oncol. 2009 Jan;10(1):61-71
19111246
Gastroenterology. 2008 Dec;135(6):1972-83, 1983.e1-11
18929564
Invest New Drugs. 2010 Oct;28(5):535-42
19554262
Mol Cancer. 2010 Jan 27;9:19
20105315
Clin Cancer Res. 2010 Jan 15;16(2):390-7
20068087
Antiviral Res. 2010 Jan;85(1):303-15
19887087
Mol Cancer. 2009 Apr 22;8:26
19386116
World J Gastroenterol. 2008 Mar 21;14(11):1657-63
18350596
JAMA. 2008 Jul 2;300(1):51-9
18594040
AIDS. 2008 Oct 18;22(16):2135-41
18832877
Lancet Oncol. 2009 Jan;10(1):25-34
19095497
Antivir Ther. 2009;14(2):155-64
19430090
Clin Cancer Res. 2006 Mar 15;12(6):1883-96
16551874
J Hepatol. 2009 Apr;50(4):736-45
19231018
Arch Intern Med. 2006 Aug 14-28;166(15):1632-41
16908797
Oncologist. 2010;15(2):142-5
20142333
J Hematol Oncol. 2008 Oct 17;1:18
18928548
Hepatology. 2005 Nov;42(5):1208-36
16250051
Gastroenterology. 2004 Nov;127(5 Suppl 1):S303-9
15508098